Radar›Companies›Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 8
United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 8

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 31 August 2026Not investment adviceRanked by Prism readiness
Readiness leaderAclaris Therapeutics · 51
Strongest available pathKura Oncology · -32.5%
Widest latest marginKeros Therapeutics · 35.7%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1ACRS · Nasdaq

Aclaris Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2012Malvern, Pennsylvania$890.6M market cap
View full Companies Radar profile
51Moderate
Snapshot price$6.05as of page date
Monthly-close return-66.4%five-year window
FY2025 revenue$0.01BAclaris Therapeutics, Inc.
Net margin-829.6%FY2025
P/E snapshot-7.5xone ratio, not a verdict
Prism attention27.3%share across these five
Filing track recordRevenue, USD billions
+15.8%
$0$0.0B$0.0B$0.0BFY2021: $0.007BFY2022: $0.030BFY2023: $0.031BFY2024: $0.019BFY2025: $0.008B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 3.7%
52-week position89% through range
$1.74$6.60
News mentions964
Community mentions11partial coverage
U.S.-scope patents239
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal68/100
Management stability90/100
Market position13/100
Capital-event signal65/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 5 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2IRWD · Nasdaq

Ironwood Pharma

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1998Cambridge, Massachusetts$702.3M market cap
View full Companies Radar profile
51Moderate
Snapshot price$4.25as of page date
Monthly-close return-67.5%five-year window
FY2025 revenue$0.30BIRONWOOD PHARMACEUTICALS INC
Net margin8.1%FY2025
P/E snapshot5.4xone ratio, not a verdict
Prism attention14.9%share across these five
Filing track recordRevenue, USD billions
-28.4%
$0$0.1B$0.3B$0.4BFY2021: $0.414BFY2022: $0.411BFY2023: $0.443BFY2024: $0.351BFY2025: $0.296B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -8.0%
52-week position68% through range
$1.01$5.78
News mentions526
Community mentions3partial coverage
U.S.-scope patents894
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal80/100
Management stability90/100
Market position11/100
Capital-event signal38/100
Innovation pulse10/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 8 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3KROS · Nasdaq

Keros Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2016Lexington, Massachusetts$219.7M market cap
View full Companies Radar profile
51Moderate
Snapshot price$11.08as of page date
Monthly-close return-72.0%five-year window
FY2025 revenue$0.24BKeros Therapeutics, Inc.
Net margin35.7%FY2025
P/E snapshot-1.7xone ratio, not a verdict
Prism attention13.0%share across these five
Filing track recordRevenue, USD billions
+1114.2%
$0$0.1B$0.2B$0.2BFY2021: $0.020BFY2023: $0.000BFY2024: $0.004BFY2025: $0.244B2021202320242025
FY2021–FY2025 · 4 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 129.8%
52-week position11% through range
$9.69$22.55
News mentions458
Community mentions5partial coverage
U.S.-scope patents174
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal87/100
Management stability70/100
Market position3/100
Capital-event signal64/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4KURA · Nasdaq

Kura Oncology

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2014San Diego, California$1.13B market cap
View full Companies Radar profile
51Moderate
Snapshot price$12.65as of page date
Monthly-close return-32.5%five-year window
FY2025 revenue$0.07BKura Oncology, Inc.
Net margin-412.9%FY2025
P/E snapshot-5.6xone ratio, not a verdict
Prism attention29.0%share across these five
Filing track recordRevenue, USD billions
+25.2%
$0$0.0B$0.0B$0.1BFY2024: $0.054BFY2025: $0.067B20242025
FY2024–FY2025 · 2 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 25.2%
52-week position81% through range
$7.36$13.90
News mentions1.0K
Community mentions23partial coverage
U.S.-scope patents483
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal68/100
Management stability90/100
Market position3/100
Capital-event signal69/100
Innovation pulse7/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 3 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5VRCA · NASDAQ

Verrica Pharmaceuticals

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2013West Chester, Pennsylvania$93.8M market cap
View full Companies Radar profile
51Moderate
Snapshot price$5.46as of page date
Monthly-close return-95.6%five-year window
FY2024 revenue$0.01BVerrica Pharmaceuticals Inc.
Net margin-1012.1%FY2024
P/E snapshot-3.7xone ratio, not a verdict
Prism attention15.8%share across these five
Filing track recordRevenue, USD billions
-37.0%
$0$0.0B$0.0B$0.0BFY2021: $0.012BFY2022: $0.009BFY2023: $0.005BFY2024: $0.008B2021202220232024
FY2021–FY2024 · 4 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -14.3%
52-week position33% through range
$3.28$9.82
News mentions559
Community mentions0partial coverage
U.S.-scope patents132
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal68/100
Management stability90/100
Market position0/100
Capital-event signal75/100
Innovation pulse15/100
Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Kura Oncology
-32.5%
Aclaris Therapeutics
-66.4%
Ironwood Pharma
-67.5%
Keros Therapeutics
-72.0%
Verrica Pharmaceuticals
-95.6%

Latest revenue

USD billions, official filing scope shown on each company card.

Ironwood Pharma
$0.30B
Keros Therapeutics
$0.24B
Kura Oncology
$0.07B
Aclaris Therapeutics
$0.01B
Verrica Pharmaceuticals
$0.01B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Keros Therapeutics
35.7%
Ironwood Pharma
8.1%
Kura Oncology
-412.9%
Aclaris Therapeutics
-829.6%
Verrica Pharmaceuticals
-1012.1%

Prism news attention

Normalized share across these five names; attention is not quality.

Kura Oncology
29.0%
Aclaris Therapeutics
27.3%
Verrica Pharmaceuticals
15.8%
Ironwood Pharma
14.9%
Keros Therapeutics
13.0%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Kura Oncology leads the conversation

It holds 29.0% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $0.07B.

Price path

Kura Oncology leads the available price paths

Its monthly-close return is -32.5% for the five-year window. At the other end, Verrica Pharmaceuticals is -95.6% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Keros Therapeutics has the widest latest margin

Its FY2025 net margin is 35.7%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Aclaris Therapeutics shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -7.5x while its five-year window price return is -66.4%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · ACRS

Aclaris Therapeutics

964available Prism news records

Prism top themes

Price action & investor response
42
Legal, arbitration & regulatory
35
Capital allocation & transactions
25
Leadership & governance
20
Earnings & financial performance
12

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-14.3%162 latest 12m vs 189 prior 12m
2024-01: 16 mentions2024-02: 3 mentions2024-03: 6 mentions2024-04: 12 mentions2024-05: 4 mentions2024-06: 8 mentions2024-07: 9 mentions2024-08: 5 mentions2024-09: 9 mentions2024-10: 7 mentions2024-11: 35 mentions2024-12: 10 mentions2025-01: 10 mentions2025-02: 50 mentions2025-03: 14 mentions2025-04: 9 mentions2025-05: 18 mentions2025-06: 13 mentions2025-07: 6 mentions2025-08: 8 mentions2025-09: 13 mentions2025-10: 1 mentions2025-11: 4 mentions2025-12: 2 mentions2026-01: 21 mentions2026-02: 22 mentions2026-03: 24 mentions2026-04: 37 mentions2026-05: 23 mentions2026-06: 1 mentions2024-012026-06

Machine-classified coverage tone

98.6% positive+1.9 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 11share price 10stock price 10phase ii trial 8phase iii trial 8angiogenesis inhibitors 7phase iv trial 7atopic dermatitis 5

Keyword tag occurrences in available Prism news records.

Coverage: 2012-09-13–2026-06-01 · trend and themes shown through 2026-06
Areas of research · KURA

Kura Oncology

1,026available Prism news records

Prism top themes

Price action & investor response
380
Legal, arbitration & regulatory
44
Macro demand & rates
34
Earnings & financial performance
27
Leadership & governance
26

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+6.7%224 latest 12m vs 210 prior 12m
2024-01: 34 mentions2024-02: 19 mentions2024-03: 16 mentions2024-04: 15 mentions2024-05: 20 mentions2024-06: 17 mentions2024-07: 6 mentions2024-08: 15 mentions2024-09: 11 mentions2024-10: 16 mentions2024-11: 31 mentions2024-12: 6 mentions2025-01: 16 mentions2025-02: 42 mentions2025-03: 17 mentions2025-04: 22 mentions2025-05: 14 mentions2025-06: 14 mentions2025-07: 7 mentions2025-08: 15 mentions2025-09: 18 mentions2025-10: 20 mentions2025-11: 27 mentions2025-12: 23 mentions2026-01: 21 mentions2026-02: 18 mentions2026-03: 18 mentions2026-04: 28 mentions2026-05: 27 mentions2026-06: 2 mentions2024-012026-06

Machine-classified coverage tone

89.5% positive-1.4 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

angiogenesis inhibitors 40leukemia driver mutations 15stock performance 14cancer biomarkers 12cytogenetic abnormalities leukemia 11phase iii trial 11employee layoff 11startup valuation 9

Keyword tag occurrences in available Prism news records.

Coverage: 2015-03-12–2026-06-03 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

ACRS

Aclaris Therapeutics

through 2025-09-18
Earnings releases 19Leadership changes 4Asset acquisitions 3Company announcements 1Listing / IPO 1
  1. Earnings releases

    For Aclaris, the consensus EPS estimate for the upcoming report has changed +2.5% over the past month to -$0.13. This represents a change of -18.2% from what the company reported a year ago.

  2. Listing / IPO

    Aclaris Therapeutics Inc. priced a public offering of about 8.6 million shares at $10.75 apiece for gross proceeds of about $92.9 million.

  3. Company announcements

    Aclaris Therapeutics, Inc. (NASDAQ: ACRS)(the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that effective December 2, 2024, the Compensation Committee of Aclaris’ Board of Directors (the “Committee”) granted nonstatutory stock options to purchase an aggregate of 251,000 shares of its common stock and 73,000 restricted stock units to 4 new employees under the Aclaris Therapeutics, Inc. 2024 Inducement Plan (the “2024 Inducement Plan”).

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

IRWD

Ironwood Pharma

through 2025-11-10
Earnings releases 11M&A 8Listing / IPO 3Company announcements 2Leadership changes 1
  1. Earnings releases

    Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) surged 27.6% to $2.45 after the company reported better-than-expected third-quarter financial results and raised its FY25 sales guidance above estimates.

  2. Company announcements

    Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 27, 2025.

  3. Listing / IPO

    Ironwood priced 16.7 million shares at $11.25 per share, generating gross proceeds of $187.9 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

KROS

Keros Therapeutics

through 2025-08-20
Company announcements 5Business contracts 1Earnings releases 1Listing / IPO 1M&A 1
  1. M&A

    Others, like Pliant Therapeutics and Keros Therapeutics, have faced investor pressure.

  2. Company announcements

    In a separate press release issued today, the Company announced its financial results for the second quarter ended June 30, 2025.

  3. Earnings releases

    Cantor Fitzgerald expects that the company will earn ($5.82) per share for the year.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

KURA

Kura Oncology

through 2026-02-06
Company announcements 21Earnings releases 6Listing / IPO 3M&A 1
  1. Company announcements

    Today announced that on February 2, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 69,750 shares of common stock to four (4) new employees under the Company’s 2023 Inducement Option Plan, as amended.

  2. Earnings releases

    Kura Oncology, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $20.75 million for the quarter ended September 2025

  3. Listing / IPO

    Kura Oncology Inc. priced an underwritten public offering with gross proceeds expected to be $67 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

VRCA

Verrica Pharmaceuticals

through 2026-04-02
Earnings releases 19Company announcements 13Leadership changes 5Regulatory 5Board updates 2
  1. Earnings releases

    Verrica Pharmaceuticals $35.58 million 2.64 -$17.89 million ($1.58) -3.46

  2. Leadership changes

    Verrica Pharmaceuticals appointed Chris Chapman as chief commercial officer.

  3. Regulatory

    On September 19, 2025, Verrica announced that its development partner, Torii, received approval from the Japanese Ministry of Health, Labour and Welfare for YCANTH ® (TO-208) for the treatment of molluscum.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence
2011 extracted base$66.70B
2016 extracted forecast$42.00B–$70.00B
Implied source CAGR9.5%
Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records
Latest 12m volume+3.4%24052 vs 23272 records
Positive classified tone65.3%+6.0 pp vs prior four quarters
2024-01: 2,385 mentions2024-02: 1,423 mentions2024-03: 1,374 mentions2024-04: 1,289 mentions2024-05: 1,487 mentions2024-06: 1,819 mentions2024-07: 1,355 mentions2024-08: 1,609 mentions2024-09: 1,720 mentions2024-10: 1,625 mentions2024-11: 1,853 mentions2024-12: 1,522 mentions2025-01: 2,799 mentions2025-02: 2,971 mentions2025-03: 2,174 mentions2025-04: 2,142 mentions2025-05: 1,683 mentions2025-06: 1,142 mentions2025-07: 1,921 mentions2025-08: 3,922 mentions2025-09: 2,081 mentions2025-10: 1,648 mentions2025-11: 1,720 mentions2025-12: 1,496 mentions2026-01: 1,701 mentions2026-02: 3,364 mentions2026-03: 1,972 mentions2026-04: 2,867 mentions2026-05: 218 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies
6,223
snowstorm and blizzard alerts
6,121
pharmaceutical marketing and sales strategies
6,014
winter weather preparedness
5,925
generic drug development and market trends
3,700
healthcare economics and market access
3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 36–43. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 31 August 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions
Comparisons
Anomalies

Kura Oncology has the widest attention-readiness rank gap

It ranks #1 by measured news attention (29.0%) and #4 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Kura Oncology in Companies Radar

Keros Therapeutics shows a price-operating divergence to inspect

Its displayed filing-revenue change is +1114.2% while its available monthly-close return is -72.0%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Keros Therapeutics in Companies Radar
Explanations

Attention measures coverage volume, not quality

Kura Oncology's 29.0% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Kura Oncology in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Aclaris Therapeutics's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 51/100 score.

Open Aclaris Therapeutics in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon